The two new ultrasound products from DiA Imaging Analysis will help in imaging and analysis of the right ventricle of the heart and the bladder.

LVivo RV and LVivo Bladder, two new AI-powered ultrasound tools from Israeli Ai specialist company DiA Imaging Analysis Ltd., have received clearance from the US Food and Drug Administration (FDA) and a European CE Mark. The LVivo RV, the first automated analysis of the right ventricle of the heart based on AI, will help to combat COVID-19 mortality linked to right ventricle heart failure. The LVivo Bladder is an AI-powered solution for automated, ultrasound measurement of bladder volume. (THE JERUSALEM POST)

LVivo RV – Right ventricle heart failure

Recent studies of the coronavirus have shown a significant correlation between COVID-19 deaths and right ventricle heart failure. A study conducted by the Mount Sinai Morningside Hospital showed that nearly 1/3 of patients admitted with COVID-19 infection had right ventricle failure, and 41% of this subset, who succumbed, had signs of right ventricle dilation or enlargement.

DiA’s LVivo RV AI-powered ultrasound tool uses a combination of advanced pattern recognition, machine learning, and deep learning algorithms. It can automatically run very quickly and accurately a 2D ultrasound analysis of the right ventricle size and function. The analysis would reveal signs, if any, of right ventricle failure.

LViVo Bladder

“We started with the cardiac area because it’s the most difficult to analyze,” said DiA CEO and co-founder Hila Goldman-Aslan to The Jerusalem Post. “Once we saw we were analyzing the main issues within the cardiac area – and with this right ventricle analysis, we’re completing the package – we knew we could start extending our focus to other parts of the body, as well.”

The company has therefore extended its focus to the abdominal area of the human body, particularly the bladder.

According to available data, healthcare-associated urinary tract infections (UTIs) account for up to 40% of infections in hospitals. Up to 23% of these infections are contracted in the intensive care unit (ICU).

DiA’s AI-powered LVivo Bladder tool provides easy ultrasound scans that prevent any unnecessary procedures or catheterization. This reduces the hazard of future infections.

DiA’s vision – democratizing the use of technology

Ultrasound is an inexpensive alternative to MRI and CT scans. However, the analysis of ultrasound images presents several problems. First, radiologists or echo cardiologists need to assess these images. Secondly, they are subject to visual estimation, which can be biased or erroneous due to images being noisy.

But AI generates automated and objective analyses that can help users understand the ultrasound images.

These users need not be radiologists or such, instead, they could be clinicians in Emergency, ICU, and other such settings.

“That’s the gap we’re closing – to help everyone use the technology easily,” says Goldman-Aslan.

Related Story:   Medical AI in A Real-World Setting is Very Different from a Lab – Google